Celldex Therapeutics Competitors and Similar CompaniesClear all
Deciphera Pharmaceuticals's competitors and similar companies include Marker Therapeutics and UCB.
 Deciphera Pharmaceuticals Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer. |  Marker Therapeutics Marker Therapeutics is a biopharmaceutical company engaged in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection. |  UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions. | |
Founding Date | Founding Date 2003 | Founding Date 2018 | Founding Date 1928 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Waltham, US HQ Lawrence, US | Locations Houston, US HQ | Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more |
Employees | Employees 35037% increase | Employees 888% decrease | Employees 9,052 |
Valuation ($) | Valuation ($) 2.2 b | Valuation ($) 36.5 m | Valuation ($) 34.3 b |
Financial | |||
Revenue (est.) | Revenue (est.) $163.4m (FY, 2023) | Revenue (est.) $3.5m (FY, 2025) | Revenue (est.) €7.4b (FY, 2025) |
Cost of goods | Cost of goods $3.7m (FY, 2023) | Cost of goods N/A | Cost of goods €1.4b (FY, 2025) |
Gross profit | Gross profit $159.6m (FY, 2023) | Gross profit N/A | Gross profit €7.2b (FY, 2025) |
Net income | Net income ($194.9m) (FY, 2023) | Net income ($12.2m) (FY, 2025) | Net income €1.6b (FY, 2025) |
For sources of this data, please see the company profile
View Company Profiles
Marker Therapeutics
HQ
Houston, US
Employees
8
Marker Therapeutics is a biopharmaceutical company engaged in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection.
View companyUCB
HQ
Brussels, BE
Employees
9,052
UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.
View company